These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 20136826

  • 1. Haematopoeitic cell transplantation for Fanconi anaemia - when and how?
    MacMillan ML, Wagner JE.
    Br J Haematol; 2010 Apr; 149(1):14-21. PubMed ID: 20136826
    [Abstract] [Full Text] [Related]

  • 2. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Tan PL, Wagner JE, Auerbach AD, Defor TE, Slungaard A, Macmillan ML.
    Pediatr Blood Cancer; 2006 May 01; 46(5):630-6. PubMed ID: 16078221
    [Abstract] [Full Text] [Related]

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 4. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience.
    Farzin A, Davies SM, Smith FO, Filipovich A, Hansen M, Auerbach AD, Harris RE.
    Br J Haematol; 2007 Feb 01; 136(4):633-40. PubMed ID: 17367413
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia.
    Yabe H, Inoue H, Matsumoto M, Hamanoue S, Koike T, Ishiguro H, Koike H, Suzuki K, Kato S, Kojima S, Tsuchida M, Mori T, Adachi S, Tsuji K, Koike K, Morimoto A, Sako M, Yabe M.
    Br J Haematol; 2006 Jul 01; 134(2):208-12. PubMed ID: 16846479
    [Abstract] [Full Text] [Related]

  • 6. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
    Chaudhury S, Auerbach AD, Kernan NA, Small TN, Prockop SE, Scaradavou A, Heller G, Wolden S, O'Reilly RJ, Boulad F.
    Br J Haematol; 2008 Mar 01; 140(6):644-55. PubMed ID: 18302713
    [Abstract] [Full Text] [Related]

  • 7. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan 01; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.
    de la Fuente J, Reiss S, McCloy M, Vulliamy T, Roberts IA, Rahemtulla A, Dokal I.
    Bone Marrow Transplant; 2003 Oct 01; 32(7):653-6. PubMed ID: 13130311
    [Abstract] [Full Text] [Related]

  • 10. Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation.
    Rossi G, Giorgiani G, Comoli P, Nobili B, Salvaneschi L, De Stefano P, Maccario R, Locatelli F.
    Bone Marrow Transplant; 2003 Mar 01; 31(6):437-40. PubMed ID: 12665837
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos EB.
    Biol Blood Marrow Transplant; 2007 Feb 01; 13(2):235-44. PubMed ID: 17241929
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 01; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 19. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S, Aker M, Shapira MY, Resnick I, Bitan M, Or R.
    Clin Transpl; 2003 Jan 01; ():275-82. PubMed ID: 15387119
    [Abstract] [Full Text] [Related]

  • 20. Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen.
    Craddock C, Bardy P, Kreiter S, Johnston R, Apperley J, Marks D, Huber C, Kolbe K, Goulding R, Lawler M, Goldman J, Hughes T, Derigs G.
    Br J Haematol; 2000 Dec 01; 111(3):797-800. PubMed ID: 11122140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.